Menu
Search
Search
Menu
Hjem
Markeder
Open submenu
Aksjer
Open submenu
Indekser
Open submenu
ETF-er
Open submenu
Fond
Open submenu
Obligasjoner
Open submenu
Strukturerte produkter
Open submenu
Derivater
Open submenu
Råvarer
Open submenu
Sustainable Finance
Open submenu
Education
Open submenu
Ressurser
Open submenu
Close submenu
Markeder
Amsterdam
Open submenu
Brussel
Open submenu
Dublin
Open submenu
Lisboa
Open submenu
Milan
Open submenu
Oslo
Open submenu
Paris
Open submenu
Close submenu
Amsterdam
Cash Products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Close submenu
Cash Products
Aksjer
Open submenu
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Close submenu
Aksjer
AEX index Stocks
AEX ESG Stocks
Close submenu
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Brussel
Cash products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Expert Market
Close submenu
Cash products
Aksjer
Open submenu
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Close submenu
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Close submenu
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Dublin
Stocks
Open submenu
Indices
Funds
Bonds
Irish Government Bonds
DOL
Close submenu
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Close submenu
Lisboa
Cash Products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Close submenu
Cash Products
Aksjer
Open submenu
Indekser
Obligasjoner
Close submenu
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Close submenu
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Milan
Cash Products
Open submenu
Derivative products
Open submenu
IPOs
Close submenu
Cash Products
Stocks
Open submenu
Bonds
Open submenu
Structured Products
Open submenu
ETFs
Funds
Close submenu
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Close submenu
Bonds
MOT
Euronext Access Milan
EuroTLX
Close submenu
Structured Products
SeDeX
EuroTLX
Close submenu
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Close submenu
Oslo
Aksjer, renter, indekser
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Finanskalender
Primærinnsidere
Close submenu
Aksjer, renter, indekser
Aksjer
Open submenu
Aksjeindekser
Obligasjoner
Open submenu
Obligasjonsindekser
ETFer
Fond
Close submenu
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Close submenu
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Close submenu
Derivater
Derivative products
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Paris
Cash Products
Open submenu
Derivater
Open submenu
Selskapsmeldinger
Open submenu
Close submenu
Cash Products
Aksjer
Open submenu
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Close submenu
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Close submenu
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Aksjer
All Markets directories
Open submenu
Selskapsmeldinger
Open submenu
Nye aksjenoteringer
Open submenu
Euronext Growth advisors
Euronext Tech Leaders
Family business
Close submenu
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Close submenu
Selskapsmeldinger
Latest
Archive
Close submenu
Nye aksjenoteringer
Alle aksjenoteringer
Close submenu
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Open submenu
Kontakter Euronext-indekser
Close submenu
Indekser høringer
Consultation MIB ESG
Consultation CAC 40 ESG
Close submenu
ETF-er
Directory
Grønne ETF-er
Close submenu
Fond
Directory
ESG Funds
Oslo Mutual Funds
Close submenu
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
Open submenu
Close submenu
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Close submenu
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Close submenu
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Close submenu
Råvarer
Quotes
Open submenu
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
DSP
Close submenu
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Close submenu
Sustainable Finance
Euronext Sustainable Network News
Sustainable Investment Forum Publications
Sustainable Partner News
Close submenu
Education
Academy
Stocks Education
Option education
Our Indices
Educational videos
News & Insights
Close submenu
Ressurser
Statistikk & rapporter
Open submenu
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Open submenu
Notices / Corporate actions
Open submenu
Markedshendelser
Open submenu
Medlemsliste
Issuers compliance
Hvor du finner hva
Close submenu
Statistikk & rapporter
Quality of execution
Close submenu
Key Information Document
Class level
Product group level
Close submenu
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
Open submenu
Derivatives notices
Close submenu
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Close submenu
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 200 av 230 resultater
Tid
Selskap
Tittel
Sektor
Kategori
01 Feb 2023
17:45 CET
NICOX
Nombre de droits de vote au 31 janvier 2023
20103015 Pharmaceuticals
Corporate life
24 Jan 2023
07:30 CET
NICOX
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023
-
New
24 Jan 2023
07:30 CET
NICOX
Nicox : Participation à des conférences financières, d’industrie pharmaceutique et scientifiques au premier semestre 2023
-
New
18 Jan 2023
07:30 CET
NICOX
Nicox Provides Fourth Quarter 2022 Financial Highlights
20103015 Pharmaceuticals
New
18 Jan 2023
07:30 CET
NICOX
Nicox : Résumé financier du quatrième trimestre 2022
20103015 Pharmaceuticals
New
09 Jan 2023
17:45 CET
NICOX
Number of voting rights as of January 9, 2023
20103015 Pharmaceuticals
Corporate life
09 Jan 2023
17:45 CET
NICOX
Nombre de droits de vote au 9 janvier 2023
20103015 Pharmaceuticals
Corporate life
09 Jan 2023
07:30 CET
NICOX
Nicox Announces Proposed Move to Euronext Growth Paris
20103015 Pharmaceuticals
New
09 Jan 2023
07:30 CET
NICOX
Nicox : Projet de transfert de la cotation des actions vers Euronext Growth Paris
20103015 Pharmaceuticals
New
06 Jan 2023
07:30 CET
NICOX
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
20103015 Pharmaceuticals
New
06 Jan 2023
07:30 CET
NICOX
Nicox : Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux
20103015 Pharmaceuticals
New
03 Jan 2023
17:45 CET
NICOX
Number of voting rights as of December 31, 2022
20103015 Pharmaceuticals
Corporate life
03 Jan 2023
17:45 CET
NICOX
Nombre de droits de vote au 31 décembre 2022
20103015 Pharmaceuticals
Corporate life
01 Dec 2022
17:45 CET
NICOX
Number of voting rights as of November 30, 2022
20103015 Pharmaceuticals
Corporate life
01 Dec 2022
17:45 CET
NICOX
Nombre de droits de vote au 30 novembre 2022
20103015 Pharmaceuticals
Corporate life
22 Nov 2022
18:45 CET
NICOX
Nicox : Mise à disposition d'un prospectus d’admission d'actions nouvelles
20103015 Pharmaceuticals
New
22 Nov 2022
12:30 CET
NICOX
Nicox : Mise à disposition d'un second amendement au Document d’enregistrement universel 2021
20103015 Pharmaceuticals
New
22 Nov 2022
07:30 CET
NICOX
Nicox Raises €10 Million in Private Placement
20103015 Pharmaceuticals
-
22 Nov 2022
07:30 CET
NICOX
Nicox Raises €10 Million in Private Placemen
20103015 Pharmaceuticals
New
22 Nov 2022
07:30 CET
NICOX
Nicox lève 10 millions d'euros avec un placement privé
20103015 Pharmaceuticals
New
07 Nov 2022
07:30 CET
NICOX
Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma
20103015 Pharmaceuticals
New
07 Nov 2022
07:30 CET
NICOX
Nicox : Plans de développement et de partenariat pour le NCX 470 dans le glaucome
20103015 Pharmaceuticals
New
02 Nov 2022
17:45 CET
NICOX
Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights AS OF OCTOBER 31, 2022
20103015 Pharmaceuticals
Corporate life
02 Nov 2022
17:45 CET
NICOX
NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 OCTOBRE 2022
20103015 Pharmaceuticals
Corporate life
31 Oct 2022
07:30 CET
NICOX
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470
20103015 Pharmaceuticals
New
31 Oct 2022
07:30 CET
NICOX
Nicox : NCX 470 atteint l’objectif primaire de l’étude Mont Blanc, la première étude de phase 3 sur le NCX 470 dans le glaucome
20103015 Pharmaceuticals
New
19 Oct 2022
07:30 CEST
NICOX
Nicox Provides Third Quarter 2022 Financial and Business Highlights
20103015 Pharmaceuticals
New
19 Oct 2022
07:30 CEST
NICOX
Nicox : Résumé financier et point d’activité du troisième trimestre 2022
20103015 Pharmaceuticals
New
03 Oct 2022
17:45 CEST
NICOX
Number of voting rights as of September 30, 2022
20103015 Pharmaceuticals
Corporate life
03 Oct 2022
17:45 CEST
NICOX
Nombre de droits de vote au 30 septembre 2022
20103015 Pharmaceuticals
Corporate life
30 Sep 2022
07:30 CEST
NICOX
Nicox confirme son éligibilité au PEA-PME
20103015 Pharmaceuticals
New
19 Sep 2022
07:30 CEST
NICOX
Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial
20103015 Pharmaceuticals
New
19 Sep 2022
07:30 CEST
NICOX
Nicox : Visite finale des derniers patients de l’étude de phase 3 Mont Blanc sur le NCX 470 dans le glaucome
20103015 Pharmaceuticals
New
16 Sep 2022
07:30 CEST
NICOX
Nicox Provides First Half 2022 Business Update and Financial Results
20103015 Pharmaceuticals
New
16 Sep 2022
07:30 CEST
NICOX
Nicox : Point des activités et résultats financiers du premier semestre 2022
20103015 Pharmaceuticals
New
15 Sep 2022
17:45 CEST
NICOX
Nicox : Rapport semestriel 2022
20103015 Pharmaceuticals
New
01 Sep 2022
17:45 CEST
NICOX
Number of voting rights as of August 31, 2022
20103015 Pharmaceuticals
Corporate life
01 Sep 2022
17:45 CEST
NICOX
Nombre de droits de vote au 31 août 2022
20103015 Pharmaceuticals
Corporate life
03 Aug 2022
07:30 CEST
NICOX
Nicox to Participate in Financial and Scientific Events in Q3 2022
20103015 Pharmaceuticals
New
03 Aug 2022
07:30 CEST
NICOX
Nicox : Participation à des conférences financières et scientifiques au troisième trimestre 2022
20103015 Pharmaceuticals
New
01 Aug 2022
17:45 CEST
NICOX
NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND TOTAL NUMBER OF VOTING RIGHTS AS OF AUGUST 1, 2022
20103015 Pharmaceuticals
Corporate life
01 Aug 2022
17:45 CEST
NICOX
NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET NOMBRE TOTAL DE DROITS DE VOTE AU 1ER AOUT 2022
20103015 Pharmaceuticals
Corporate life
29 Jul 2022
07:30 CEST
NICOX
Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
20103015 Pharmaceuticals
New
29 Jul 2022
07:30 CEST
NICOX
Nicox : Jean-François Labbé nommé Président du Conseil d’administration
20103015 Pharmaceuticals
New
20 Jul 2022
07:30 CEST
NICOX
Nicox Provides Second Quarter 2022 Financial and Business Highlights
20103015 Pharmaceuticals
New
20 Jul 2022
07:30 CEST
NICOX
Nicox : Résumé financier et point d’activité du deuxième trimestre 2022
20103015 Pharmaceuticals
New
08 Jul 2022
07:30 CEST
NICOX
Nicox: 2022 Extraordinary Shareholder Meeting
20103015 Pharmaceuticals
New
08 Jul 2022
07:30 CEST
NICOX
Nicox : Assemblée Générale Extraordinaire 2022
20103015 Pharmaceuticals
New
07 Jul 2022
07:30 CEST
NICOX
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology
20103015 Pharmaceuticals
New
07 Jul 2022
07:30 CEST
NICOX
Nicox : Publication de nouvelles données sur le NCX 470 montrant des améliorations de l’hémodynamique oculaire et de la physiologie des cellules rétiniennes
20103015 Pharmaceuticals
New
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Close menu
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window